The Pharma Data

AUGUST 3, 2021

In the first half of 2021, Boehringer Ingelheim has supplied more humans and animals worldwide with innovative medicines than ever before. Our strong R&D pipeline has made further, decisive progress in the first half of 2021. These medical successes have the potential to improve the lives of millions of patients worldwide.”.

Research 52

Research Treatment Clinical Trials Production 52

Broad Institute

OCTOBER 11, 2023

But immunotherapy was not yet widely used and had not been applied clinically to Merkel cell carcinoma, so she received traditional chemotherapy and radiation therapy, suffering life-threatening complications along the way. His mother had a presentation of the disease that suggested her immune system was already on the job.

Research 137

Research Immune Response Clinical Trials Therapies 137

The Pharma Data

JANUARY 17, 2021

PRIME is a program launched by EMA to optimize development plans and speed up evaluation of medicines that demonstrate major therapeutic advantage over existing treatments, or otherwise benefit patients without treatment options. . These results were published in Journal of Clinical Oncology ( Ramos et al., BEDMINSTER, N.J.

Therapies 40

Therapies Clinical Development Treatment Trials 40

The Pharma Data

JANUARY 12, 2021

Working alongside KSQ will facilitate smart drug discovery and development of what we hope will be transformative new therapies for patients with intractable forms of cancer.”. KSQ and Takeda can collaborate on IND-enabling activities, with clinical development led by Takeda to explore multiple modalities.

Therapies 52

Therapies Immune Response Research Engineering 52

The Pharma Data

DECEMBER 8, 2020

9, 2020 /PRNewswire/ — The members of the Nomination Committee for BioInvent International AB :s (publ) (“BioInvent) Annual General Meeting in 2021 have now been appointed. The Annual General Meeting will be held on April 29, 2021 in Lund, Sweden. LUND, Sweden , Dec. Chairman of the Nomination Committee.

Clinical Trials 40

Clinical Trials Licensing Licensing International 40

The Pharma Data

SEPTEMBER 8, 2021

today announced that data reinforcing the potential of immunotherapies to impact clinical outcomes for patients will be featured at the European Society for Medical Oncology (ESMO) 2021 Virtual Congress from September 16-21. Early Development. Summary of Presentations. All times noted are Central European Summer Time (CEST).

Research 52

Research Immune Response Treatment Trials 52

The Pharma Data

DECEMBER 21, 2020

UBX1325 is developed from BM-962, a Bcl-xL inhibiting compound licensed to UNITY by Ascentage Pharma for the treatment of age-related diseases. This progress in clinical development qualifies Ascentage Pharma for a milestone payment according to the terms of the licensing agreement. SUZHOU, China and ROCKVILLE, Md. ,

Clinical Development 40

Clinical Development Disease Treatment Licensing 40

The Pharma Data

JANUARY 20, 2021

20, 2021 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. The offering is expected to close on or about January 25, 2021, subject to satisfaction of customary closing conditions. The Company is developing a novel class of investigational antibody therapeutics, based on our Probody ® technology platform, for the treatment of cancer.

Clinical Development 40

Clinical Development Therapies Drugs Science 40

LifeSciVC

JANUARY 16, 2024

These are incredible forecasts and CAGRs, which if we assume directionally correct, rely not only on steady growth for approved therapies but also a substantial success rate of, and continued investment in, the development pipeline.

Small Molecule 137

Small Molecule Trials Therapies Disease 137

Creative Biolabs

MAY 25, 2022

Fu, 2022) Clinical research progress of ADC After decades of efforts, more than 100 ADCs are currently under clinical development. As of December 2021, 14 Antibody-drug conjugate drugs have been approved for sale in different countries around the world.

Therapies 52

Therapies Drugs DNA Treatment 52

The Pharma Data

JULY 23, 2021

(Nasdaq: BIIB) today announced it will share multiple oral and poster presentations from its Alzheimer’s disease clinical development portfolio at the Alzheimer’s Association International Conference (AAIC), which will be held in Denver, Colorado and online July 26-30, 2021.

International 52

International Disease Clinical Trials Trials 52

The Pharma Data

MARCH 17, 2021

Gallen International Breast Cancer Conference Poster Awards 2021. Gallen will be published in a supplement issue of The Breast, available on March 17, 2021. Accepted as ePoster – Adjuvant Systemic Therapy. Available on-demand on March 10, 2021. Gallen International Breast Cancer Conference Poster Awards 2021.

Trials 52

Trials Therapies Treatment Pharmacokinetics 52

The Pharma Data

SEPTEMBER 11, 2021

– Designation is based on results from the EMPEROR-Preserved phase III trial, which established Jardiance as the first therapy to show statistically significant improvement in heart failure outcomes in adults with heart failure with preserved ejection fraction. vice president, Product Development, Lilly.

Therapies 52

Therapies FDA Hospitals FDA Approval 52

The Pharma Data

APRIL 11, 2021

The data were presented at the 2021 American Association for Cancer Research (AACR) Annual Meeting, held virtually April 10-15, 2021. was approved by the European Commission in February 2021. The Phase 1/2 LIBRETTO-001 trial is the largest clinical trial of patients with RET -driven cancers treated with a RET inhibitor.

Research 52

Research Therapies Treatment Trials 52

Drug Target Review

JANUARY 15, 2024

About the author Daniel Kavanagh, PhD, RAC Senior Scientific Advisor, Gene Therapies, Vaccines and Biologics at WCG Dr Kavanagh engages with sponsors, CROs and research institutions on topics related to human gene transfer research. Engineering soluble T-cell receptors for therapy. The FEBS Journal 288:6159–6173 (2021).

Engineering 110

Engineering DNA Virus Immune Response 110

The Pharma Data

DECEMBER 9, 2020

This acquisition will significantly strengthen Boehringer Ingelheim’s focus on targeted cancer cell therapies, gaining the company access to NBE’s innovative immune-stimulatory iADC platform. . Initial results for the open-label study are expected in 2021. billion US. .

FDA Approval 52

FDA Approval Clinical Development Therapies Vaccine 52

The Pharma Data

JANUARY 27, 2021

27 , 2021 /PRNewswire/ — Harbour BioMed (HBM) (HKEX: 02142.HK), HK), announced today that China Center for Drug Evaluation (CDE) has granted Breakthrough Therapy designation to Batoclimab (HBM 9161), a fully human anti-FcRn monoclonal antibody (mAb), for the treatment of adult patients with Myasthenia Gravis (MG).

Therapies 40

Therapies Treatment International Licensing 40

The Pharma Data

JANUARY 17, 2021

18, 2021 09:00 UTC. LONDON–( BUSINESS WIRE )– Ixaka Ltd , an integrated cell and gene therapy company focused on the natural power of the body to cure disease, launches today. Our focus is now on accelerating progress to help realise the potential for durable and curative cell and gene therapies. A total of $15.4

Therapies 40

Therapies Clinical Trials Disease Immune Response 40

The Pharma Data

JANUARY 18, 2021

18, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. The fireside chat is scheduled to take place on Wednesday, January 20, 2021 at 2:30 PM ET. The fireside chat is scheduled to take place on Wednesday, January 20, 2021 at 2:30 PM ET. © 2021 Sorrento Therapeutics, Inc. SAN DIEGO, Jan.

Clinical Trials 40

Clinical Trials Small Molecule Trials Therapies 40

The Pharma Data

JANUARY 14, 2021

15, 2021 /PRNewswire/ — Calliditas Therapeutics AB (publ) (“Calliditas”) (Nasdaq OMX – CALTX) (NASDAQ – CALT) today announced the program for the upcoming virtual R&D Day for investors, analysts and journalists on January 20, 2021 , which will take place between 1pm and 5pm CET. STOCKHOLM , Jan.

Clinical Trials 40

Clinical Trials Disease Hospitals International 40

The Pharma Data

JANUARY 12, 2021

13, 2021 /PRNewswire/ — EVOQ Therapeutics today announced a license and collaboration agreement with Amgen for the discovery and development of novel drugs for autoimmune disorders. ANN ARBOR, Mich. ,

Licensing 52

Licensing Licensing Biosimilars Clinical Development 52

The Pharma Data

MARCH 27, 2021

Dr. Martin will assume responsibility for Gilead’s research organization effective April 12, 2021. Gilead has outstanding research and clinical development programs across Virology, Immunology and Oncology, and I am tremendously excited to be joining an organization with such a deep and talented scientific core,” commented Dr. Martin.

Science 52

Science Research Clinical Development Pharmacy 52

The Pharma Data

APRIL 7, 2022

“At Pfizer, we have a strong heritage in, and commitment to, fighting infectious diseases, most recently evidenced by our delivery of the first authorized vaccine and oral therapy to combat COVID-19,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. Sisunatovir has been granted Fast Track designation by the U.S.

Virus 52

Virus Vaccine Clinical Development Hospitals 52

Drug Target Review

DECEMBER 27, 2023

Aside from CD24, there are several other ‘don’t eat me’ signals that have been characterised, and there are multiple programmes currently in clinical development that target these signals. About the author Dr Roy Maute Cofounder & Chief Scientific Officer, Pheast Therapeutics Dr Maute joined Pheast Therapeutics in 2021.

Immune Response 105

Immune Response Science Clinical Development Drugs 105

Agency IQ

FEBRUARY 12, 2024

BY RACHEL COE, MSC | FEB 7, 2024 10:21 PM CST The Bespoke Gene Therapy Consortium A collaborative effort, the Bespoke Gene Therapy Consortium (BGTC) was launched in October 2021 to “accelerate development of gene therapies for the 30 million Americans who suffer from a rare disease.”

FDA 40

FDA Therapies Clinical Trials Disease 40

The Pharma Data

JANUARY 21, 2021

22, 2021 12:00 UTC. –( BUSINESS WIRE )– Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced an oral presentation on updated efficacy, safety, and dosing management of poziotinib from Cohorts 1 and 2 of the ZENITH20 clinical trial.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Licensing Licensing 52

The Pharma Data

JULY 28, 2021

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for avalglucosidase alfa, a long-term enzyme replacement therapy for the treatment of people with Pompe disease. Avalglucosidase alfa is also currently undergoing review in other countries including the U.S.,

Disease 52

Disease Therapies FDA Clinical Development 52

The Pharma Data

NOVEMBER 2, 2020

Xpovio was initially green lit by the FDA last year in combination with dexamethasone for the treatment of patients with relapsed refractory multiple myeloma who have received at least three prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent and one anti-CD38 monoclonal antibody.

FDA 52

FDA Treatment Therapies Clinical Development 52

The Pharma Data

JANUARY 7, 2021

Pivotal Data Anticipated in 2021 to Support Potential Registration, Addressing an Estimated Market Opportunity of Greater than $500 Million. a privately-held, clinical-stage biotechnology company developing imipridones, a novel class of compounds. The final confirmatory data analysis is expected in 2021.

Clinical Trials 52

Clinical Trials Small Molecule Trials Therapies 52

Drug Target Review

OCTOBER 16, 2024

It’s an exciting process—anticipating development risks, predicting outcomes, and aligning these with the greater vision of medical advancement. The true joy comes from navigating these complexities and asking the right questions early on, because these foundational steps are critical to the success of any clinical development process.

Clinical Development 52

Clinical Development Drug Development Therapies Disease 52

The Pharma Data

JANUARY 26, 2021

27, 2021 07:00 UTC. LEIDEN, The Netherlands–( BUSINESS WIRE )– VarmX , a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the appointment of Dr. Gerard Short, MBBS, as Chief Medical Officer (CMO).

Clinical Development 40

Clinical Development Medical Schools Therapies Pharmaceuticals 40

The Pharma Data

JANUARY 21, 2021

The 2021 trend of biotech initial public offerings (IPOs) continued this week. Precigen is focused on next-generation gene and cell therapy using precision technology. On January 5, 2021, the U.S. The National Institutes of Health (NIH) is planning on taking over manufacturing and clinical development.

Immune Response 52

Immune Response Laboratories Trials Therapies 52

Drug Target Review

NOVEMBER 30, 2023

Our investigational active immunisation therapies could potentially delay or perhaps even prevent the onset of clinical dementia symptoms. We – as a team – are very proud to be advancing these products, three of which are in mid- to late-stage clinical development. I would say, first and foremost, to believe in yourself.

Disease 95

Disease Therapies Laboratories Treatment 95

The Pharma Data

JANUARY 27, 2021

28, 2021 11:00 UTC. The Company is in late-stage clinical development and has been working toward establishing commercial readiness. This webinar will give current and prospective investors a clear vision of the Company’s goals for 2021 and beyond. CLEVELAND, Ohio–( BUSINESS WIRE )– Athersys, Inc.

Clinical Trials 52

Clinical Trials Trials Therapies Production 52

The Pharma Data

NOVEMBER 8, 2021

Data from the analyses were presented at the American Society of Nephrology (ASN)’s Order Week 2021 in two oral donations and two late- breaking bills. The cardiology ballot at Bayer formerly includes a number of products and several other composites in colorful stages of preclinical and clinical development.

Clinical Trials 52

Clinical Trials Trials Therapies Treatment 52

The Pharma Data

JUNE 25, 2021

Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for lecanemab (BAN2401), an investigational anti-amyloid beta (A?) Breakthrough Therapy designation is an FDA program intended to expedite the development and review of medicines for serious or life-threatening conditions. and clinical decline.

Disease 40

Disease Treatment Therapies FDA 40

The Pharma Data

JULY 22, 2021

This should significantly enhance and accelerate the development and potential commercialization of ARV-471 while also advancing Arvinas’ strategy of building a global, integrated biopharmaceutical company,” said John Houston, Ph.D., Chief Scientific Officer for Oncology Research and Development at Pfizer.

Targeted Protein Degradation 52

Targeted Protein Degradation Therapies Clinical Trials Treatment 52